HOME >> MEDICINE >> NEWS
Researchers develop better understanding of tamoxifen resistance in breast cancer patients

Washington, D.C. A new study by researchers at Georgetown's Lombardi Comprehensive Cancer Center may have implications for the thousands of breast cancer patients who develop resistance to antiestrogen drugs such as Tamoxifen. The work is published in the June 1 issue of Cancer Research.

The study, led by Robert Clarke, Ph.D., D.Sc., professor of oncology, shows that there may be an association between the gene IRF 1 (Interferon Regulatory Factor) and breast tumor resistance to tamoxifen or other antiestrogen treatment. IRF 1 is a tumor suppressor gene not previously associated with breast cancer.

"We hope that by pinpointing the connection between IRF 1 and breast cancer, we may be able to better identify which patients will respond to antiestrogen treatment and which patients will ultimately develop antiestrogen resistance," said Clarke.

Antiestrogen therapy is currently the most effective means to manage hormone-dependent breast cancer and has the fewest serious side effects. Hormone-dependent breast cancer accounts for approximately one-third of all breast cancer cases. The most widely prescribed antiestrogen therapy is tamoxifen, which blocks the activity of the estrogen hormone in breast tissue and can increase patients' overall survival. However about a third of breast tumors that might be expected to respond (because they express receptors for estrogen) are resistant to antiestrogens from the onset of treatment, and many initially responsive tumors sooner or later become resistant.

The Lombardi researchers studied a series of antiestrogen-sensitive and antiestrogen-resistant human breast cells using a variety of different microarray technologies.

"The logical implication of our work is that by adding the protein interferon to antiestrogen therapy, we should be able to turn on the IRF 1 gene to make these tumors sensitive to antiestrogen therapy, hopefully inhibiting new breast cancers or reoccurrences
'"/>

Contact: Elizabeth McDonald
eem6@georgetown.edu
202-687-7707
Georgetown University Medical Center
9-Jun-2004


Page: 1 2

Related medicine news :

1. Researchers search for first sign of congestive heart failure
2. Researchers say breast cancer in Africa may provide clues to the disease in African-Americans
3. Researchers close in on breast cancer vaccine
4. Researchers discover link between insulin and Alzheimers
5. Researchers model brains electrical storm during a seizure
6. Researchers track programs success in curbing aggressive behavior
7. Researchers confirm Vioxx nearly doubled cardiovascular risks in cancer prevention study
8. Researchers offer emergency workers a lifeline
9. Researchers discover genetic variant that may explain why women develop M.S. more than men
10. Researchers map the sexual network of an entire high school
11. Researchers hope monkeys can provide new insights into depression

Post Your Comments:
*Name:
*Comment:
*Email:


(Date:10/13/2017)... ... 2017 , ... “America On The Brink”: the Christian history of the United ... the creation of published author, William Nowers. Captain Nowers and his wife, Millie, ... spent thirty years in the Navy. Following his career as a naval aviator ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company has developed a ... and regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been ... standard. , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, ...
(Date:10/12/2017)... ... , ... The American College of Medical Informatics (ACMI) will present the 2017 ... Session of AMIA’s Annual Symposium in Washington, D.C. AMIA’s Annual Symposium is ... pioneer in the field of medical informatics, this prestigious award is presented to an ...
(Date:10/12/2017)... ... 12, 2017 , ... Information about the technology: , Otomagnetics ... enable prevention of a major side effect of chemotherapy in children. Cisplatin and ... For cisplatin, hearing loss is FDA listed on-label as a dose limiting toxicity. ...
Breaking Medicine News(10 mins):
(Date:10/12/2017)... 2017 AVACEN Medical , Inc. (AVACEN) announced ... 2017 New Product Innovation Award for Its fibromyalgia pain ... secondary medical device market research by Frost & Sullivan,s industry ... drug-free pain relief product, the AVACEN 100, offers a safe ... widespread pain. ...
(Date:10/12/2017)... 12, 2017 West Pharmaceutical Services, Inc. ... for injectable drug administration, today announced that it will ... on Thursday, October 26, 2017, and will follow with ... expectations at 9:00 a.m. Eastern Time. To participate on ... The conference ID is 94093362. ...
(Date:10/11/2017)... 2017  Caris Life Sciences ® , a leading ... of precision medicine, today announced that St. Jude Medical ... Alliance™ (POA) as its 17 th member. Through ... Crosson Cancer Institute will help develop standards of care ... profiling, making cancer treatment more precise and effective. ...
Breaking Medicine Technology:
Cached News: